MDK — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL17167232	0.61	6/20
SCHEMBL13431412	0.61	6/20
SCHEMBL13431415	0.61	6/20
SCHEMBL13431465	0.61	6/20
SCHEMBL13431404	0.60	6/20
SCHEMBL17167238	0.57	6/20
SCHEMBL17167191	0.56	6/20
SCHEMBL17167223	0.54	6/20
SCHEMBL13596920	0.54	6/20
SCHEMBL13596930	0.54	6/20
SCHEMBL17167254	0.53	6/20
SCHEMBL15060648	0.53	6/20
SCHEMBL12931125	0.53	6/20
SCHEMBL13321881	0.51	6/20
SCHEMBL16645717	0.50	6/20
SCHEMBL17167195	0.48	6/20
SCHEMBL13321885	0.61	5/20
SCHEMBL13321878	0.61	5/20
SCHEMBL17167701	0.59	5/20
SCHEMBL13431463	0.56	5/20

Clinical trials — most relevant to MDK by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Chemotherapy Drug Sensitivity Microculture (MiCK) Assay for Apoptosis	PHASE2/PHASE3	COMPLETED
Cardiac Effects of Mineralocorticoid Receptor Antagonism After Preeclampsia	PHASE2	RECRUITING
Valuation of the Safety and Efficacy of Combination of Cryoablation and Dendric Cell/Cytokine-induced Killers Cells Treatment for Advanced Liver Cancers	PHASE1/PHASE2	UNKNOWN
Bryostatin 1 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer	PHASE2	COMPLETED
A Safety and Efficacy Study of Carbidopa-levodopa in Patients With Macular Degeneration	PHASE2	WITHDRAWN
Dose Ranging Study of Carbidopa-levodopa	PHASE2	COMPLETED
Immunotherapy Without Chemotherapy for Advanced Lung Cancer Patients With High PD-L1 Levels	PHASE2	NOT_YET_RECRUITING
Cytokine Induced Killer (CIK) Cells In Leukemia Patients	PHASE2	COMPLETED
Carbidopa-levodopa in Neovascular AMD	PHASE2	COMPLETED
Long Non Coding RNA HOTAIR and Midkine as Biomarkers in Thyroid Cancer	nan	UNKNOWN
Feasibility Study of MicroKine Dx System in Critically-ill Pediatric Patients.	nan	UNKNOWN
Relation Between Cachexia, Diabetes and periNeural Invasion in PANcreatic Cancer- Biomarkers Substudy	nan	COMPLETED
Myokine Identification Following Acute Exercise	nan	COMPLETED
Mediating Role of Myokines in the Dialogue Between Muscle and Bone Tissue in a Population of Healthy Women Aged 20-89 Years	nan	RECRUITING
Reduction of Muscle Catabolism Through Brain Activation in Burn Patients	nan	NOT_YET_RECRUITING
The Irisin and Metabolic Exercise Training Study	nan	COMPLETED
OvS Breast: Ovarian Suppression in Breast Cancer Interventions	nan	RECRUITING
How Exercise Signals Health Responses	nan	COMPLETED
Serum circ_DLGAP4, lncRNA KCNQ1OT1, and Their Targets by Erythropoietin Resistance in Chronic Kidney Disease	nan	COMPLETED
Assessment of Disease Severity, Progression and Treatment in Infected Patients Presenting to the Emergency Department	nan	COMPLETED
Effects of Exercises on Total Body Health in Children With Acute Lymphoblastic Leukemia	nan	COMPLETED
Comparison of Serum Myokine Dosages and Imaging Methods in the Evaluation of Sarcopenia in Patients With Hepatocellular Carcinoma	nan	RECRUITING
Assessment of ProEnkephalin to Detect Acute Kidney Injury (AKI)	nan	COMPLETED
Clinical Study on the Application of PET Probes Targeting DDR2 in the Diagnosis of Interstitial Lung Disease With Cognitive Impairment	nan	NOT_YET_RECRUITING
Investigating the Metabolic and Lipidomic Profiles That Are Associated With Varying Grades of Diabetic Maculopathy and Retinopathy in South Wales	nan	RECRUITING
Ozurdex in Suboptimal Diabetic Macular Edema Patients	nan	UNKNOWN
Markers of Tissue Injury and Rhabdomyolysis in Patients With Major Trauma	nan	COMPLETED
Myostatin and Irisin Levels in Predicting the Outcome of Patients With Systemic Inflammation: A Prospective Observational Study	nan	COMPLETED
Irisin Hormone as a Novel Diagnostic Marker for Detection and Progression of Diabetic Nephrophathy Patients	nan	NOT_YET_RECRUITING
The Bone-Myoregulation Reflex and Development of Sarcopenia in Osteoporosis	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a MDK binder may also engage these)

Protein	Name	Similarity
Q9R1S9	—	0.995	Q9R1S9 →
P12025	—	0.994	P12025 →
P24052	—	0.993	P24052 →
P48530	—	0.993	P48530 →
Q6P8F3	—	0.992	Q6P8F3 →
P48531	—	0.989	P48531 →
P48533	—	0.980	P48533 →
P48532	—	0.978	P48532 →
O54775	—	0.963	O54775 →
P19336	—	0.960	P19336 →
Q8VCC9	—	0.958	Q8VCC9 →
Q9ES72	—	0.955	Q9ES72 →
P35447	—	0.955	P35447 →
O00622	—	0.955	O00622 →
A5A6L1	—	0.954	A5A6L1 →
Q2MKA7	—	0.954	Q2MKA7 →
P0C5H9	—	0.953	P0C5H9 →
P35446	—	0.953	P35446 →
P18572	—	0.953	P18572 →
Q5XHC5	—	0.953	Q5XHC5 →
Q99PP0	—	0.953	Q99PP0 →
A0A6I8RMG7	—	0.952	A0A6I8RMG7 →
A2A863	—	0.952	A2A863 →
ERP29	Endoplasmic reticulum resident protein 29	0.952	landscape →
P80513	—	0.952	P80513 →
Q8R553	—	0.952	Q8R553 →
P34007	—	0.951	P34007 →
Q6Q7I7	—	0.951	Q6Q7I7 →
P31696	—	0.951	P31696 →
Q9WUA1	—	0.950	Q9WUA1 →